Do Statins Lower Your Coronary Artery Calcium Score?

Statins do not lower your coronary artery calcium score. In fact, they tend to raise it. Across randomized trials and observational studies, people taking statins consistently show equal or greater progression in their CAC scores compared with people not taking them, and higher-dose statins push the score up faster than lower doses. This sounds alarming until you understand what the calcium score actually measures and what statins are doing to the plaque underneath. The rising number on your scan report does not mean the drug is failing you.

What the Calcium Score Tells You

A coronary artery calcium score quantifies the amount of calcified plaque in the arteries that feed your heart. It is measured by a CT scan and calculated using the Agatston method, which factors in both the area of calcium deposits and their peak density. The result is a single number: zero means no detectable calcified plaque, while scores in the hundreds or thousands indicate substantial buildup. A higher score signals a greater overall burden of coronary atherosclerosis, which is why the test is used to help decide whether someone at borderline risk should start preventive treatment like a statin.¹

The score has real predictive power. A score of zero confers very low risk of major cardiovascular events over a decade or more. A score above 100, by contrast, puts a person in a meaningfully higher risk category where statins offer a substantial benefit. One large analysis following over 13,000 patients for roughly nine years found that the number of people you would need to treat with a statin to prevent one major cardiovascular event was 3,571 among those with a zero score, compared with just 12 among those scoring above 100.² That enormous gap explains why doctors use the initial CAC scan to sharpen their recommendations. But using repeat scans to track whether a statin is “working” is a different question entirely, and the answer is less intuitive.

Why Statins Push the Score Up

Reanalyzed data from two randomized trials showed that patients on placebo and those on low-dose atorvastatin had similar calcium progression over one to two years, while patients on the highest dose of atorvastatin saw their calcium increase an additional 12 to 14 percent beyond the placebo group. Over the longer term, statin-treated patients continued to accumulate more calcium than those on placebo.³ Observational data tells a similar story. In a study of patients with chronic kidney disease followed for four years, those on statins were about 78 percent more likely to show CAC progression than those not taking statins.⁴

The critical detail in the trial data: despite greater calcium progression, patients on statins did not have more cardiovascular events. The researchers who reanalyzed those trials interpreted the extra calcium as plaque repair, not plaque expansion.³ This counterintuitive finding is sometimes called the statin-CAC paradox, and understanding it requires looking at what is happening inside the plaque rather than just measuring the calcium on top.

Plaque Stabilization Versus Plaque Growth

Not all plaque is equally dangerous. The plaques most likely to rupture and cause a heart attack tend to be soft, lipid-rich, and covered by a thin fibrous cap. Calcified plaques, by contrast, are generally more stable. Think of it as the difference between a blister about to pop and a callus that has hardened over.

Statins shift the composition of plaque toward that harder, more stable state. Imaging studies using coronary CT angiography have shown that statin therapy is associated with reductions in the volume of soft, low-density plaques and fatty plaques, while the volume of high-density calcified plaques increases.⁵ In other words, the plaque does not necessarily grow in total size; it trades dangerous soft material for denser, more stable calcified material. Longer-term statin users show a similar pattern: fewer soft unstable plaques, more calcified ones.⁶

Earlier randomized trials that looked only at total calcium volume or Agatston score changes on standard CT scans could not detect this compositional shift. Because those trials measured total calcium but not calcium density, they found no difference between statin and placebo groups and seemed to suggest statins had no effect at all on calcification. One analysis noted that the statins’ ability to reduce formation of new soft plaque may have been offset by accelerated calcification of existing noncalcified plaque, producing an apparent wash.⁷ The real story was hidden inside the plaque, invisible to the standard scoring method.

Why Calcium Density Matters More Than the Score

The Agatston score was designed in the 1990s and bundles two different things together: how much calcium there is and how dense that calcium is. Those two components carry opposite risk signals. Greater calcium volume correlates with more disease. But denser calcium, for a given volume, correlates with fewer events. A systematic review and meta-analysis found that higher calcium density was associated with about a 20 percent lower risk of cardiovascular events per standard-deviation increase, after accounting for the total volume of calcium and other clinical risk factors.⁸

Data from the large, long-running MESA study confirmed that separating volume and density gives better risk prediction than the Agatston score alone. When calcium volume was relatively low, higher density was strongly associated with lower risk of coronary heart disease. At larger calcium volumes, the protective association of density weakened but the direction stayed the same.⁹ This distinction matters for statin users because statins appear to shift plaque toward denser calcification. If you are on a statin and your Agatston score climbs, the score may be going up partly because you are accumulating denser, more protective calcium rather than simply piling on more disease.

Current standard reporting still uses the Agatston score, so you and your doctor are working with a number that mixes helpful and harmful signals together. That is one reason why tracking your score over time while on a statin is not very informative: a rising number does not reliably tell you whether things are getting worse or the plaque is just hardening.

Should You Get a Repeat Scan on a Statin?

Probably not. Guidelines discourage frequent repeat CAC testing because it has limited clinical value once a treatment decision has been made, adds cost, can trigger unnecessary follow-up tests, and exposes you to a small amount of radiation with each scan.¹⁰ The main exception is someone whose initial score was zero: repeating the scan after about five years can be reasonable to see whether detectable plaque has appeared in the interim, since a zero score can shift to a positive one as a person ages.

For people already on a statin, the score is expected to rise, and that rise does not predict worsening outcomes. Monitoring your LDL cholesterol, blood pressure, and other modifiable risk factors is a far more useful way to gauge whether treatment is working. A repeat CAC scan in this context is more likely to cause anxiety than to change your care plan.

The Biological Mechanisms Behind Statin-Induced Calcification

Researchers have identified several molecular pathways through which statins promote arterial calcification. One well-studied mechanism involves a protein called Rac1. Statins block the chemical modification that normally keeps Rac1 in an inactive state. Once freed, Rac1 triggers the expression of inflammatory signaling molecules, including IL-1β, which promote the deposition of calcium in vessel walls.¹¹

Another proposed mechanism involves vitamin K. Vitamin K is essential for activating proteins that help keep calcium out of arterial walls and directed toward bones. One study found that statin users had significantly elevated levels of undercarboxylated osteocalcin, a marker of vitamin K deficiency, suggesting that statins may impair the activation of vitamin K-dependent proteins involved in protecting blood vessels from calcification.¹² This does not mean you should start supplementing vitamin K2 on your own. The clinical significance of this finding is still being worked out, and no large trial has yet shown that adding vitamin K to a statin regimen changes cardiovascular outcomes. But it does open an interesting window into why statins accelerate calcification beyond the simple plaque-stabilization story.

How Inflammation Changes the Picture

Your baseline level of inflammation may influence how aggressively statins push calcification forward. In a secondary analysis of a statin trial, patients with higher levels of high-sensitivity C-reactive protein, a marker of systemic inflammation, developed significantly more dense calcified plaque over two years of statin treatment compared with patients who had lower inflammation levels. The relationship held even after adjusting for LDL cholesterol, blood pressure, and statin intensity.¹³

Interestingly, while dense calcified burden increased more in the high-inflammation group, overall CAC scores did not differ between the high and low inflammation groups. That finding further illustrates why the Agatston score is a blunt instrument: it can miss compositional changes that matter for risk. It also suggests that the plaque-stabilizing calcification driven by statins may be partly an inflammatory response to treatment, one that produces stable calcified tissue rather than the dangerous microspots of calcium associated with plaque rupture.¹⁴

Do PCSK9 Inhibitors Behave Differently?

PCSK9 inhibitors are injectable drugs that lower LDL cholesterol dramatically, often added to a statin when cholesterol remains stubbornly high. Their effect on coronary calcium appears somewhat different from that of statins alone. One study found that patients on a PCSK9 inhibitor plus a statin had roughly half the annual rate of CAC progression compared with patients on statin monotherapy: about 14 percent per year versus about 30 percent per year.¹⁵

When it comes to plaque composition, though, a trial of the PCSK9 inhibitor evolocumab found no difference between the drug and placebo in changes to calcified, fibrous, fibrofatty, or necrotic plaque volumes on intravascular ultrasound.¹⁶ So PCSK9 inhibitors slow overall CAC progression when added to statins, but they do not seem to actively alter the makeup of individual plaques the way statins do. The evidence here is still relatively thin, and the clinical implications of a slower calcium rise versus a faster one are not settled.

Sex Differences in CAC-Guided Statin Decisions

CAC scoring does not play out identically for men and women, and understanding this matters if you are a woman wondering whether your scan results mean the same thing they would for a man. In the large CLARIFY study, among patients whose standard risk calculators already recommended a statin, CAC scoring was more likely to downgrade that recommendation in women than in men: 66 percent of women versus 52 percent of men were reclassified to a lower risk tier where a statin might not be needed. Conversely, among those not initially recommended a statin, CAC moved a smaller share of women than men into the eligible category.¹⁷

There is evidence that for a given CAC score, women may face a somewhat higher cardiovascular risk than men, though this has not yet changed the official score thresholds used in practice.¹⁸ Women in the CLARIFY study were also 24 percent less likely than men to receive high-intensity statins even after accounting for their CAC results, and they saw smaller reductions in LDL cholesterol at one year.¹⁷ Whether this gap reflects appropriate clinical judgment, undertreatment, or differences in patient preferences is still debated, but it is worth being aware of if you are a woman interpreting a CAC result with your doctor.

AI and Opportunistic Screening

One development that may make CAC information more widely available is the use of artificial intelligence to detect coronary calcium on chest CT scans that were ordered for other reasons, such as evaluating a lung nodule or checking for pneumonia. These scans are not specifically designed to measure calcium, but a deep learning algorithm can flag significant coronary calcification in the images and alert the ordering physician.¹⁹ The idea is that many people who have never had a formal cardiac calcium scan already have CT data sitting in hospital systems. Mining it could identify patients with unrecognized disease who might benefit from preventive treatment. This approach sidesteps the cost and radiation of a dedicated scan, though it provides rougher quantification than a gated cardiac CT would.

For someone already on a statin, AI-detected calcium on a routine chest scan is subject to the same interpretive challenges described throughout this article. A high reading does not mean your statin is failing; it means calcium is present, which in the context of active treatment may reflect plaque stabilization rather than unchecked disease growth. The utility of these AI tools is primarily in flagging people who have never been assessed at all, not in replacing formal follow-up scans for patients already under treatment.

1
PubMed Central. An Update on Coronary Artery Calcium Interpretation at Chest and Cardiac CT
2
PubMed Central. Coronary Artery Calcium Score as a Graded Decision Tool
3
International Journal of Cardiology. Effect of statin therapy on coronary artery calcium progression rates in clinical trials
4
Kidney International Reports. Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study
5
American College of Cardiology. The Effect of Statin Therapy on the Progression and Composition of Coronary Atherosclerotic Plaque Identified on Coronary CTA
6
American Journal of Preventive Cardiology. The impact of lipid-lowering medications on coronary artery plaque characteristics
7
JAMA Cardiology. Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition
8
PubMed. Coronary Artery Calcium Density and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis
9
PubMed Central. Coronary Artery Calcium Density and Cardiovascular Events by Volume Level: The MESA
10
Global Cardiology. Coronary artery calcium scoring. What clinicians need to know
11
PubMed Central. Long-term statin therapy is associated with severe coronary artery calcification
12
PubMed Central. Statins, vascular calcification, and vitamin K-dependent proteins: Is there a relation?
13
PubMed Central. Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study
14
PubMed Central. The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review
15
npj Aging and Mechanisms of Disease. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
16
PubMed. Effect of Evolocumab on Coronary Plaque Composition
17
PubMed Central. Impact of low/no-charge coronary artery calcium scoring on statin eligibility and outcomes in women: The CLARIFY study
18
Journal of Clinical Lipidology. Coronary artery calcium scoring and statin therapy in women
19
PubMed Central. Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)